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Available online 23 July 2011Abstract Improving cardiac differentiation of human pluripotent stem cells is mandatory to provide functional heart muscle
cells for novel therapies. Here, we have investigated the enhancing effect of the small molecule SB203580, a p38 MAPK
inhibitor, on cardiomyogenesis in hESC by monitoring the phosphorylation patterns of the major MAPK pathway components
p38, JNK and ERK by western immunoblotting.
A remarkable drop in phosphorylation levels of all three MAPK pathways was induced after overnight embryoid body (EB)
formation. Upon further differentiation, phosphorylation dynamics in EBs were specifically altered by distinct inhibitor
concentrations. At 5 μM of SB203580, cardiomyogenesis was most efficient and associated with the expected p38 pathway
inhibition. In parallel, JNK activation was observed suggesting a regulatory interlink between these pathways in hESC ultimately
supporting cardiac differentiation. In contrast, moderately elevated SB203580 concentrations (15–30 μM) resulted in complete
disruption of cardiomyogenesis which was associated with prominent inhibition of ERK and further elevated JNK activity.
We propose that a tightly-balanced pattern in MAPK phosphorylation is important for early mesoderm and subsequent
cardiomyocyte formation. Our data provide novel insights into molecular consequences of small molecule supplementation in
hESC differentiation, emphasizing the role of MAPK-signaling.
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Estimations suggest that more than one billion cardiomyocytes
will be required per patient for cardiac replacement therapies
after myocardial infarction (Murry et al., 2006). Human
embryonic stem cells (hESC) present an attractive cell source
to generate cardiomyocytes on a large scale, which could be
applied not only for cell therapy, but also for drug screening.
199MAPK pathways in cardiac differentiation of hESCand cardiotoxicity tests (Zweigerdt, 2007). Despite
recent improvements using growth factor supplemented
media (Kattman et al., 2011), differentiation in chemically
defined culture media with high relevance for clinical
translation only achieved differentiation efficiencies in the
range of 10–30% cardiomyocytes from hESC (Kehat, 2001;
Yang et al., 2008; Xu et al., 2008; Laflamme et al., 2007).
Thus, improvements in cardiomyogenesis from hESC and also
human induced pluripotent stem cells (hiPSC) are much
needed.
Recently, several reports have shown that small mole-
cules effectively support maintenance, differentiation and
reprogramming of mouse as well as human embryonic stem
cells indicating their potential in replacing natural growth
factors to direct these processes (Borowiak et al., 2009; Zhu
et al., 2009; Ying et al., 2008; Hanna et al., 2010; Lyssiotis
et al., 2009). Compared to natural growth factors, small
molecules have the advantage of being synthetic and are
therefore relatively inexpensive and more amenable for
Good Manufacturing Practice (GMP) (Kirouac and Zandstra,
2008). However, most of the reports only describe the
phenotypic effects of the small molecules but do not
examine the underlying molecular mechanisms. Understand-
ing the molecular mechanisms however, might provide
insights for developing rational protocols to improve current
differentiation methodologies.
Several of the recent publications use small molecules
that target various proteins of the Mitogen-Activated Protein
Kinase (MAPK) signaling pathway (Ying et al., 2008; Graichen
et al., 2008; Chen et al., 2006; Shan et al., 2007). The MAPK-
pathway consists of three-tiered core modules of protein
kinases that are ubiquitously expressed in all eukaryotic
cells. Upstream MAP Kinase–Kinase–Kinases (MAP3Ks) phos-
phorylate downstream MAPK Kinase–Kinases (MAP2Ks) that
in turn activate MAPK further downstream, leading to a
sequential signaling cascade predominantly within the
cytoplasm. MAPK signaling is known to play an essential
role for several tightly regulated cellular functions such as
proliferation, differentiation, migration and apoptosis
(Wada and Penninger, 2004; Dong et al., 2002; Zarubin and
Han, 2005).
The MAPK family belongs to the group of serine/
threonine kinases and consists of at least 11 members in 6
different subgroups, among them the 3 major groups of
extracellular signal-regulated protein kinases (ERK 1 and
ERK 2), c-UN NH2-terminal kinases (JNK 1, JNK 2, JNK 3)
and p38 MAP kinases (p38-α,-β,-γ and-δ) (Geest and
Coffer, 2009). While the ERK family is reported to play an
important role in the balance of proliferation and
apoptosis, JNK and p38 are generally associated with
cellular stress responses.
Common to all MAPKs is their conserved tripeptide motif
Thr-Xaa-Tyr (whereas Xaa is any amino-acid), which is dually
phosphorylated upon activation. MAPK then transduce
signals to their nuclear and cytoplasmic substrates, predom-
inantly other kinases and transcription factors.
We have recently shown that the small molecule p38
MAPK (mitogen-activated protein kinase) inhibitor SB203580
can significantly enhance cardiomyogenesis in hESC in a
concentration dependent manner (Graichen et al., 2008). It
was shown that addition of the molecule at an optimal
concentration of 1–10 μM enhanced the cardiac differenti-ation yield by 2.5-fold, while a high concentration of
15–30 μM favored neuro-ectodermal differentiation. How-
ever the effect of the molecule on the molecular level was
not investigated.
SB203580 is a pyridinyl imidazole compound inhibiting the
p38 MAPK (Cuenda, 1995) by blocking the ATP binding site
and is reported to be specific for the α and β isoforms (Young
et al., 1997; Kumar et al., 1997). However, an impact of the
molecule on the ERK and JNK pathway regulation has also
been reported (Karaman et al., 2008; Henklova et al., 2008;
Muniyappa and Das, 2008; Ishii et al., 2001; Clerk and
Sugden, 1998; Hall-Jackson et al., 1999). In this report we
have elucidated the effect of the small molecule SB203580
on p38 related MAPKs and provided data that might explain
opposing effects of the molecule when applied at different
concentrations.
We report here an overall decrease of MAPK phosphory-
lation during EB-induction prior to addition of SB203580. This
low phosphorylation state is fine-tuned by low concentra-
tions of SB203580. Interestingly, SB203580 results not only in
the expected inhibition of p38, but also activates the JNK
pathways. However, elevated concentrations of SB203580
impair this tight MAPK balance and inhibit in particular the
ERK pathway and result in suppression of cardiomyogenesis.
We therefore propose that the MAPK phosphorylation
pattern achieved by low concentrations of SB203580 is
essential for mesodermal differentiation and enhanced
cardiomyogenesis.
Results
Single addition of 5 μM SB203580 induces significant
increase of earlymesodermalmarkers expression and
cardiomyogenesis
An enhancing effect of SB203580 on hESC cardiomyogen-
esis has been demonstrated in various differentiation
platforms such as END2 conditioned media, defined serum
free media and microcarrier cultures (Xu et al., 2008;
Graichen et al., 2008; Lecina et al., 2010; Gaur et al.,
2010). To provide a basis for the current study we have
established a differentiation platform in a chemically
defined medium (illustrated in Fig. 1) and confirmed that
at a 5 μM inhibitor concentration a significantly higher
percentage of beating EBs and cardiomyocyte formation
was induced compared to spontaneous differentiation in
DMSO (solvent of SB203580; Figs. 2 A–C). In contrast,
addition of SB203580 at higher concentrations i.e. 15 μM
and 30 μM resulted in significantly lower amounts of
beating aggregates and numbers of cells expressing
cardiomyocyte-specific markers (Figs. 2 A–B), in line
with prior findings (Xu et al., 2008; Graichen et al.,
2008). Interestingly, analysis on day 16 of differentiation
revealed a reduced overall cell count at 15 μM and
significantly lower cell numbers at 30 μM SB203580
compared to DMSO and 5 μM of SB203580 conditions
indicating loss of cell vitality and/or proliferation at
higher inhibitor concentrations (Fig. 2 D).
To narrow down the critical period of SB203580
activity within the differentiation process repeated
treatment with 5 μM of the inhibitor (every 3 days) was
Figure 1 Overviewof thedifferentiationprocedure.Humanembryonic stemcells (hESC)were transferred to suspension culture in basic
serum-free media (bSFS) for embryoid body (EB) formation at day −1. After EB formation for 1 day, cells were stimulated with SB203580
(day 0). After cultivation for up to 16 days EBs were characterized. Western Blot analysis was performed between day −1 and day 1.
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Results showed that a single addition of SB203580 was
sufficient to induce an equivalent amount of beating at
day 14 compared to multiple additions (Fig. 2 E).
Moreover gene expression analysis for mesodermal (T-
bra and Mesp1) and early cardiac (Nkx2.5) markers was
performed for DMSO and 5 μM SB203580 conditions (Fig. 2
F). A significant increase in T-bra and Mesp1 expression
compared to DMSO was already observed 1 day after
addition of SB203580. In contrast to early peaks of T-bra
and Mesp1 expression at day 1, Nkx2.5 levels continuously
increased from day 1 onwards in the presence of
SB203580. In summary, these results demonstrate that a
single addition of SB203580 24 h post-induction signifi-
cantly induces cardiomyogenesis.High MAPKs phosphorylation in hESC and substantial
drop after EB induction independent of the culture
medium
A phosphorylation pattern of MAPKs is yet poorly studied in
hESC. We thus established the phosphorylation status of
key pathway components in undifferentiated hESC and
described the effect of EB induction. Western blot analysis
with phospho-sensitive antibodies for HSP27 and the three
predominant groups of MAPKs – p38, JNK and ERK – was
performed. Interestingly, undifferentiated hESC in main-
tenance medium (KO-SR) showed relatively high phosphor-
ylation for all measured MAPKs and HSP27 (Fig. 3 A).
However, overnight EB formation (that is 24 h after hESC
transfer in suspension culture; designated day 0 in Fig. 3 A)
induced a clear drop of phosphorylation for all measured
proteins (Figs. 3 A–B). This drop was independent of the
culture medium applied in suspension culture (KO-SR or
bSFS) and sustained when tested after 8 h (Fig. 3 A). We
noted, however, that ERK 1/2 phosphorylation was
somewhat higher in bSFS medium compared to KO-SR in
suspension.
The overall levels of the respective proteins remained
essentially unchanged before and after EB induction.
Only HSP27 was up-regulated in EBs compared to hESCwhich led to an even lower HSP27 phosphorylation ratio
(Fig. 3 B).
The observed phosphorylation pattern was further con-
firmed at 24 hours post EB induction by additional western
blots in bSFS medium shown by densitometric analysis of at
least 3 independent experiments for HSP27, p38, JNK and
ERK in Fig. 3 B.
In summary, a significant drop in MAPKs phosphorylation
was induced by transferring hESC into suspension culture
EBs. This drop was apparently independent of differentiation
medium as it was also observed in the maintenance medium
KO-SR supplemented with bFGF.Sustained inhibition of the p38 pathway in EBs by
5 μM SB203580
To evaluate the capability of SB203580 to suppress the p38
pathway in our system, we analyzed the phosphorylation of
p38 and its specific downstream target HSP27 (Zarubin and
Han, 2005; Cuenda, 1995; New et al., 1998; Xu et al., 2006)
in EBs treated with 5 μM SB203580 (Fig. 4 A). Our data
demonstrate that despite relatively low p38 phosphorylation
in EBs the level was significantly reduced after 30 minutes
treatment with 5 μM SB203580 compared to DMSO controls
(Fig. 4 A). This effect was sustained for at least 8 h. In line
with this observation, HSP27 phosphorylation was also
reduced subsequently to SB203580 treatment (Fig. 4 A).
Notably, p38 and HSP27 phosphorylation were not further
suppressed at 30 μM SB203580, indicating nearly complete
inhibition of the p38 pathway at 5 μM SB203580 (Supple-
mentary Fig. 1).
To substantiate the capability of 5 μM SB203580 to suppress
the p38 pathway activity in our system the MAPK-activating
compound anisomycin was applied (Fig. 4 B) (Zinck et al.,
1995). Addition of anisomycin at 5 μM resulted in strong
phosphorylation induction of p38 and HSP27 after 30 min
(Fig. 4 B) which was maintained for at least 8 h (Supplementary
Fig. 2). Phosphorylation was almost completely blocked when
SB203580 was added simultaneously as confirmed by the p38
and HSP 27 phosphorylation patterns (Supplementary Fig. 2).
Figure 2 Enhanced cardiomyogenesis in hESC by single addition of 5 μM SB203580. (A) Percentage of beating embryoid bodies (EBs)
at 5, 15 and 30 μM SB203580 between day 9 and 16 after differentiation induction. (B) Flow cytometry data of the cardiac markers
myosin heavy chain (α-MHC) and sarcomeric actinin (SA) of EBs harvested 16 days after differentiation induction. (C) Gene expression
of α-MHC at day 9 after differentiation induction at 5 μM SB203580 compared to control (DMSO). (D) Cell count of harvested EBs
16 days after differentiation induction. (E) Percentage of beating EBs after single (day 0) and multiple (days 0, 2, 5, 8 and 11) addition
of SB203580 compared to control (DMSO). (F) Gene expression analysis of the early cardiac markers T-bra, Mesp1 and Nkx2.5 relative
to expression in hESC and normalized to GAPDH. Day −1 refers to gene expression in undifferentiated hESC in KO-SR; day 0 refers to the
time point of SB203580 addition to EBs cultivated in bSFS media. Error bars represent standard error of the mean. One way ANOVA
followed by Bonferroni's multiple comparison test compared to DMSO was performed in A, B, D, E and student t-tests in C and F.***,
Pb0.001; **, Pb0.01; *, Pb0.05; n.s. not significant.
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differentiation. Single addition of 5 μM anisomycin to EBs on
day 0 was toxic (data not shown). Titration experiments
revealed that 50 nM anisomycin was tolerated by the cells
but resulted in complete blockage of cardiac differentiation
(Fig. 4 C); this supports the notion that activating p38 blocks
cardiomyogenesis. Importantly, this block was reversed by
simultaneous treatment with 5 μM SB203580 (Fig. 4 C and
Supplementary Fig. 3).Together these data demonstrate that endogenous as well
as induced p38 pathway activity interferes with cardiomyo-
cyte formation in hESC, which is remediated by SB203580.
Activation of JNK and inhibition of ERK at high
SB203580 concentrations
In addition to the p38 pathway we have further investigated
the phosphorylation patterns of other MAPKs known to be
Figure 3 Phosphorylation patterns of MAPKs during EB formation of hESC. (A) Representative western blot analysis for p38, Hsp27,
JNK and ERK. Phosphorylated and total proteins were detected for undifferentiated hESC controls and after overnight EB induction in
bSFS or KO-SR in suspension culture at two time points: after overnight incubation (d0) and 8 h later (d0+8 h). GAPDH was used as
loading control on each individual blot. (B) Densitometry data of phosphorylation ratios for p38 and HSP27 (upper panel), JNK isoforms
(middle panel) and ERK isoforms (lower panel) in bSFS media. Data is relative to phosphorylation ratio of hESC. Error bars represent
standard error of at least four independent experiments. Ratio is relative to undifferentiated hESC (−24 h). One way ANOVA followed
by Bonferroni's multiple comparison was performed to test for significance. ***, Pb0.001; **, Pb0.01; *, Pb0.05.
202 H. Kempf et al.directly or indirectly affected by SB203580 in different
human cell types (Henklova et al., 2008; Muniyappa and Das,
2008; Ishii et al., 2001; Clerk and Sugden, 1998; Hall-Jackson
et al., 1999).
We first focused on the second group of stress-activated
MAPKs JNK 1, JNK 2 and JNK 3 (Fig. 5 A)whichwere suggested to
facilitate the maintenance of undifferentiated hESC in their
phosphorylated state (Brill et al., 2009). Interestingly, phos-
phorylation of all JNK isoforms, which was high in hESC and
nearly absent in DMSO-treated EB controls, was significantly
reactivated 30 min after addition of 5 μM SB203580 (Fig. 5 B). A
further increase at 30 μM suggests concentration-dependent
activation of JNK in response to SB203580 addition, which
maintained for at least 8 h (Fig. 5 A). Increased JNK activity was
statistically significant at 5 and 30 μM SB203580 compared to
DMSO control shown by densitometry analysis (Fig. 5 B),
although it was less pronounced compared to hESC and
anisomycin-treated cells (Fig. 5A).
To test the relevance of JNK activation in cardiac
differentiation, the specific JNK inhibitor SP600125 was
applied at 10 μM. Single addition at day 0 was sufficient to
block cadiomyogenic differentiation. In contrast to anisomy-cin treatment, simultaneous addition of 5 μM SB203580 did
not rescue the differentiation (Supplementary Figs. 3 and 4).
Analysis of the third major group of MAPKs (ERK 1 and ERK 2)
showed no apparent difference in phosphorylation in EBs
treated with 5 μM SB203580 compared to DMSO controls
(Fig. 5 C). However, addition of the inhibitor at a 30 μM
concentration significantly decreased the phosphorylation level
after 30 min; this decrease was sustained 8 h after treatment
(Fig. 5 C). Densitometry data at 30 μM revealed a reduction by
N50% of the phosphorylation ratios of ERK 1 and ERK 2 (Fig. 5 D)
compared to 5 μM SB203580 and DMSO controls.
Addition of anisomycin revealed strong activation of JNK 1,
JNK 2 and JNK 3 in EBs in response to the agent but essentially
no effect on ERK phosphorylation in line with published data
for other human cell lines (Zinck et al., 1995).Discussion
Supplementation of the p38 MAPK inhibitor SB203580 has
been identified to enhance cardiomyogenesis of human
embryonic stem cells at a relative narrow range of 1–10 μM
Figure 4 Inhibitory capability of SB203580 on p38 pathway. (A) p38 (upper panel) and HSP27 (lower panel) phosphorylation patterns
of hESC cultured in KO-SR compared to EBs after overnight incubation (d0) in bSFS media. EBs were treated with 5 μM SB203580 for
30 min (left panel) and 8 h (right panel). (B) p38 (upper panel) and HSP27 (lower panel) phosphorylation patterns of EBs stimulated for
30 min with 5 μM SB203580, 5 μM anisomycin or both. GAPDH was used as internal control. Phosphorylation ratios were calculated from
densitometry data and are shown for each blot. Error bars represent standard error of at least three independent experiments.
Student's t-test was applied to test for significances between treatments with 5 μM SB203580 and control (DMSO). (C) Flow cytometry
data for the cardiac markers myosin heavy chain (α-MHC) and sarcomeric actinin (SA) (left panel) and percentage of beating EBs (right
panel) at day 14 of differentiation. Error bars represent standard error of 4 independent experiments. One way ANOVA followed by
Bonferroni's multiple comparison test was performed. ***, Pb0.001; **, Pb0.01; *, Pb0.05; 5 μM — 5 μM SB203580; AM — anisomycin;
EB — embryoid body.
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cardiac differentiation (Graichen et al., 2008). This process
has been described only on the cellular level and by gene
expression analysis. It was therefore the aim of this study to
firstly, perform a systematic examination of MAPKs phos-
phorylation patterns in pluripotent hESC and secondly, to
elucidate the underlying mechanisms of the small molecule
effector on its target p38 and associated proteins. Our results
revealed a broad range of MAPK phosphorylation dynamics
upon induction of hESC differentiation in suspension.Notably, addition of SB203580 to EBs did not only result in
p38 inhibition, but also affected other MAPK in a concentra-
tion dependent manner.
We first established a differentiation protocol based on a
chemically defined medium supplemented with SB203580
(Xu et al., 2008; Lecina et al., 2010). Our data showed
enhanced cardiac differentiation at 5 μM SB203580 com-
pared to DMSO controls, but suppression of cardiomyogenesis
at 15 μM and 30 μM concentrations, confirming findings by
Graichen et al. and others (Graichen et al., 2008; Gaur et al.,
Figure 5 Effects of 5 μM and 30 μM SB203580 on JNK and ERK (A) JNK 1 and JNK 2/3 phosphorylation patterns of hESC cultured in KO-SR
and of EBs after overnight incubation (d0) in bSFS media. EBs were treated with 5 μM, 30 μM SB203580 or anisomycin (AM) for 30 min
(d0+0.5 h) and 8 h (d0+8 h). (B) Phosphorylation ratios of JNK 1 and JNK 2/3 calculated from densitometry data (C) ERK 1 and ERK 2
phosphorylation patterns of hESC cultured in KO-SR and of EBs after overnight incubation (d0) in bSFS media. EBs were treated with 5 μM,
30 μM SB203580 or anisomycin (AM) for 30 min (d0+0.5 h) and 8 h (d0+8 h). (D) Phosphorylation ratios of ERK 1 and ERK 2 calculated from
densitometry data. GAPDH was used as internal control. Error bars represent standard error of three independent experiments. Student's
t-test was conducted to determine significances between treatments. **, Pb0.01; *, Pb0.05. SB — SB203580.
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reproducible and therefore suitable for detailed analysis on
the molecular level.
In undifferentiated hESC, we found relatively high MAPKs
phosphorylation levels (see schematic summary in Fig. 6 A)
whereas 24 hours post EB formation a drop in phosphoryla-
tion of N50% for all three predominant MAPKs – p38, JNK,
ERK – and the p38 downstream target HSP27 was observed
(Fig. 6 B). To our knowledge, such drastic, global decrease of
MAPKs phosphorylation in response to hESC differentiation
induction has not been reported. However, some previous
findings for JNK and ERK support our data. Brill and
coworkers detected low phosphorylation of JNK in differen-
tiated hESC by Mass Spectrometry (MS) compared to
undifferentiated cells (Brill et al., 2009). In this work,
application of JNK inhibitors resulted in loss of pluripotency
markers, suggesting that hESC differentiation is accompa-
nied by low JNK phosphorylation levels. This is furthersupported by data showing a decrease of c-Jun phosphory-
lation, a major downstream target of JNK, within 4 h after
BMP4-induced differentiation in hESC (Van Hoof et al.,
2009). Likewise, high ERK phosphorylation was previously
reported to be required for self-renewal in undifferentiated
hESC (Li et al., 2007) whereas low ERK phosphorylation
was associated with EBs after 14 days of differentiation
(Armstrong, 2006). Inhibition of ERK phosphorylation by
small molecules including U0126 has also been shown to
induce hESC differentiation (Li et al., 2007; Armstrong, 2006).
The pronounced inhibition of the p38 MAPK pathway that is
decreased p38 and HSP27 phosphorylation, shown by us has
not been described in vitro previously. Notably, in silico
predictions attributed a central role to p38 phosphorylation in
controlling hESC differentiation (Van Hoof et al., 2009).
Such drastic changes in major components of conserved
and ubiquitous MAPKs pathways suggest that they play key
roles in EB-induced hESC differentiation processes.
Figure 6 Model of MAPK activity in SB-enhanced cardiomyogenesis. (A) Mitogen-activated protein kinases (blue boxes) show high
phosphorylation (black arrow heads; relative arrow head size represent relative phosphorylation throughout the model) in
undifferentiated human embryonic stem cells (hESC) colonies characterized by high self-renewal and proliferation potential. High
MAPK activity results in activation (blue arrows) of HSP27. EB-based differentiation (grey arrows) results in overall reduction of MAPK
phosphorylation; but distinct patters established in response to the addition of DMSO (B), 1–10 μM SB203580 (C) and concentrations
above 15 μM SB203580 (D). Differentiation in DMSO conditions (B) is characterized by low (JNK, p38) and intermediate (ERK) activity of
MAPKs associated with permissive low cardiac differentiation potential. Due to low p38 activity, activation of HSP27 is also low. At
1–10 μM SB203580 (C), p38 activity is directly inhibited (red arrow) through binding of SB203580 to the ATP-binding pocket of p38.
Consequently HSP27 is not activated by p38 (black cross). Furthermore lack of p38 activity, results in disruption of the negative
feedback loop (black cross). The common upstream activator (MAPK3K) of p38 and JNK is not inhibited, resulting in increased JNK
activity. In addition, JNK activation is potentially mediated by other additional (direct) interactions of SB203580. Importantly, ERK
activity is not affected at 5 μM SB203580. Concentrations above 15 μM SB203580 (D) do not show additional effects on p38, but result in
higher JNK activity and clear inhibition of ERK activity. This impaired phosphorylation pattern is associated with suppression of cardiac
differentiation and loss of cell viability.
205MAPK pathways in cardiac differentiation of hESCImportantly, this decline in phosphorylation was indepen-
dent of hESC transfer into differentiation medium and lack of
growth factor (e.g. bFGF) supplementation, as controlexperiments were conducted in several culture media
including hESC maintenance medium. Therefore, our data
suggest that MAPKs dephosphorylation occurs generally in
206 H. Kempf et al.response to transition from hESC colony growth in 2D to 3D EB
suspension culture.
Despite low endogenous p38 activity in early EBs, we
demonstrated that p38 and HSP27 phosphorylation are
further down-regulated upon addition of 5 μM SB203580
(Fig. 4 and schematic summary in Fig. 6 C). According to the
literature, even such minor changes of p38 activity might
explain the profound changes in the differentiation process-
es due to the high sensitivity of MAPK signal transduction
(Huang and Ferrell, 1996; Kholodenko, 2000; O'Shaughnessy
et al., 2011). Control experiments showed that exogenous
activation of p38 by anisomycin resulted in complete
blockage of cardiac differentiation, which was rescued by
simultaneous addition of SB203580. This emphasizes the
essential role of p38 pathway inhibition in hESC differenti-
ation to cardiomyocytes.
Regarding JNK, phosphorylation levels were either mod-
erately (for JNK 1) or significantly increased (for JNK 2/3) at
5 μM SB203580 compared to DMSO controls; these effects
were further pronounced at 30 μM (Figs. 5 A–B, schema in
Figs. 6 C–D). This suggests a concentration-dependent
activation of JNK by SB203580, which has been described
to be a MAPK3K-regulated process as shown for various
human cell types (Henklova et al., 2008; Muniyappa and Das,
2008). In the literature, it has been suggested that TAK1, a
MAPK3K member, is the intermediary that activates both,
p38 and JNK. Activation of p38 in turn leads to inhibition of
TAK1 via TAB1 (TAK1-binding protein 1). This negative
feedback loop is disrupted upon addition of SB203580,
which subsequently results in a higher TAK1 activity and
consequently JNK phosphorylation as well (Fig. 6 C)
(Heinrichsdorff et al., 2008; Cheung et al., 2003; Hall and
Davis, 2002; Gaestel et al., 2009). To what extent this
compensatory mechanism contributes to SB203580-en-
hanced cardiomyogenesis in hESC needs further investiga-
tion. However, given that even minor modification in MAPK
activity might result in profound changes in cell fate, it is
plausible to assume that the moderate up regulation of JNK
phosphorylation at 5 μM SB203580 might be causative for
increased cardiomyogenesis. This was confirmed by applying
the JNK inhibitor, SP600125. Results showed abrogation of
cardiac differentiation after single treatment with
SP600125, which was not rescued by SB203580, in contrast
to anisomycin treatment. These findings suggest that JNK
activity is necessary for cardiomyocyte formation in line with
previous findings from mESC which described an essential
role of the JNK pathway in mesoderm and cardiac differen-
tiation (Xu and Davis, 2010; Sato et al., 2005).
In contrast to JNK, ERK phosphorylation was apparently
not affected at a 5 μM SB203580 concentration (Figs. 5 C–D,
6 C) but remained at a relatively high level in EBs, which
might support cell viability and some degree of proliferation.
However, at 30 μM, ERK phosphorylation was significantly
reduced (Figs. 5 C–D, 6 D). According to in vitro studies,
SB203580 can affect the ERK pathway by direct inhibition of
c-Raf upstream of ERK (Hall-Jackson et al., 1999). As cell
proliferation is correlated with high phosphorylation levels
of ERK (Geest et al., 2009; Wang et al., 2009), inhibition of
this pathway might explain the significant drop in cell count
which we have observed at 30 μM SB203580 (Fig. 2D). The
pronounced ERK inhibition at the high inhibitor concentra-
tions might also directly be related to suppressed cardio-myogenic differentiation, as the importance of ERK activity
in mesoderm i.e. T-bra induction in hESC was recently
pointed out by Yu et al., in line with our observation (Yu et
al., 2011). It is also worth noting that in mice, ERK pathway
activity was shown to be necessary for mesoderm differen-
tiation (Yao, 2003).
Also in mice, activity of HSP25, the mouse homolog of
the human HSP27 downstream of p38, is necessary for
functional cardiac differentiation (Davidson and Morange,
2000). Another study showed that expression of HSP27 is
essential for preventing differentiating mouse ESC from
undergoing apoptosis (Mehlen et al., 1997). The transcrip-
tion factor MEF2C, a downstream target of p38, is essential
for early embryonic cardiovascular development (Yang et
al., 2000) and the expression of the cardiac-specific gene
TNNI3K (Wang et al., 2008). In addition, ATF-2, a third
downstream target of p38, was reported to play a critical
role in cardiomyocyte differentiation (Monzen et al.,
2001). Thus, at least in the mouse system, direct links
between MAPKs pathways regulation and cardiomyogenic
differentiation are well established.
However, in contrast to hESC, it is reported that
activation rather than inhibition of MAPK signaling
cascades results in cardiovascular commitment in mouse
ESC, including a crucial role for ROS (reactive oxygen
species)-induced p38 activation (Schmelter et al., 2006).
Furthermore, p38 activity was required in mouse-derived
P19 embryonal carcinoma cells for cardiomyocyte differ-
entiation (Yang et al., 2000; Eriksson, 2002). In both
studies, administration of different MAPK inhibitors
(SB203580, UO126 and SP600125) disrupted cardiomyo-
genesis in mESC. Also, ERK phosphorylation is low in
undifferentiated mESC in contrast to hESC (Dvorak et al.,
2005). Instead of inducing differentiation as described for
hESC, inhibition of the ERK pathway by small molecules
helps to maintain the cells in an undifferentiated state.
These observations suggest that species-specific differ-
ences exist, requiring careful assessment of a given
system.
In summary, our work is an important step to
understand and to control phosphorylation dynamics in
human pluripotent stem cell maintenance and differenti-
ation. This is the first report that provides a detailed
analysis of MAPKs regulation in hESC in response to a small
molecule inhibitor. We have shown that a drastic
decrease in phosphorylation of the three predominant
MAPKs – p38, JNK and ERK – is induced upon EB formation.
Secondly, in early EBs, addition of 5 μM SB203580 resulted
in further reduction of p38 phosphorylation but a
moderate increase of JNK phosphorylation, which subse-
quently lead to increased cardiomyogenesis. Since p38
and HSP27 phosphorylation were essentially undetectable
already at 5 μM SB203580, higher concentrations appar-
ently did not further affect the p38 pathway. In contrast,
dominant JNK activation and clear ERK inhibition were
observed, which was accompanied by a reduction in
cardiomyogenesis and loss of cell viability. These results
highlight the importance of a delicate balance of MAPKs
pathway regulation for lineage-specific differentiation in
hESC and explain the divergent effects of the small
molecule inhibitor within a relative narrow range of
concentrations.
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hESC culture and differentiation
The human embryonic stem cell line HES-3 (karyotype 46,
XX) from ES Cell International was cultured on mitomycin-C
immortalized mouse feeders (ΔE-MEF) in daily replaced
KNOCKOUT (KO) medium containing 10 ng/ml bFGF (Invitro-
gen) as described previously (Lecina et al., 2010; Choo et al.,
2006).
For differentiation, hESC were harvested as described
previously (Lecina et al., 2010) and seeded at about 1×106
cells/ml on ultra-low attachment 12-well plates (Nunc) in
bSFS medium: DMEM (Invitrogen) supplemented with 2 mM
L-glutamine (Invitrogen), 0.182 mM sodium pyruvate (Invi-
trogen), 1% non-essential amino acids (Invitrogen), 0.1 mM
β-mercaptoethanol, 5.6 mg/L transferrin (Invitrogen) and
20 ug/L sodium selenite (Sigma). In control experiments, KO-
medium containing 10 ng/ml bFGF was used. After agitation
for 10 min at 70 rpm at 37 °C cells were incubated for 1 day
at 37 °C and 5% CO2 to allow EB formation. Cells were
stimulated with SB203580, SP600125 and anisomycin in equal
amounts of DMSO (Sigma-Aldrich). Unless otherwise noted,
medium was refreshed every 2–3 days (Fig. 1).
Quantification of beatings
Differentiation experiments were evaluated morphologically
at 4× magnification (EVOS microscope) from day 8 onwards
every 2–3 days. Each embryoid body (EB) of minimal
diameter (approximately 200 μm) was observed for at least
10 s and considered positive when the body contained at
least one beating focus.
Western blot
Total protein was extracted with lysis buffer (Cell Signaling
Technology) containing 1 mM PMSF and quantified with the
660 nm Protein Assay (Pierce). 10 μg proteins were separat-
ed on 4–12% gradient Bis-Tris NuPage gels (Invitrogen) and
transferred electrophoretically onto methanol-activated
PVDF membrane (Millipore). After blocking for 1 h room
temperature (LI-COR blocking buffer), membranes were
incubated overnight at 4 °C with primary antibodies recog-
nizing phosphorylation or entire protein. Anti-GAPDH was
used as loading control. Primary antibody was visualized
using species-selected secondary antibody with the Odyssey
Infrared Imaging System (Li-Cor Biosystems). Manufacturer's
software was used for densitometry analysis. All antibodies
used are shown in Supplementary Table 1.
Quantitative RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen)
following the supplier's protocol. Reverse transcription was
carried out with 1 μg total RNA using SuperScript III
(Invitrogen). Real-time PCR was performed applying a
standard two-step amplification protocol on an ABI 7500
system (Applied Biosystem) to detect mRNA expression
(sequences are shown in Supplementary Table 2).Cell quantification
Cell count was determined using NucleoCounter (Chemome-
tec) according to the manufacturer's instruction.
Flow cytometry
EBs were harvested 16 days after differentiation induction by
incubation for 30 min in PBS without Ca2+ and Mg2+
(Invitrogen) containing 700 Units/ml collagenase Type IV
(Sigma) and 20% FBS (HyClone) at 37 °C, followed by
treatment with 0.25% trypsin/EDTA (Invitrogen) for 2 min.
The harvested single suspension cells were fixed and
permeabilized (FIX&PERM, Invitrogen) according to manu-
facturer's instruction. Cells were incubated with anti-
sarcomeric actinin (dilution at 1:100 Sigma-Aldrich) and
anti-sarcomeric MHC (MF20 at 1:200, Hybridoma Bank)
antibodies for 1 h and detected with an appropriate
Fluorescein isothiocyanate-conjugated antibody (1:500;
DAKO) on FACSCalibur (BD Biosciences) using CellQuest Pro
software.
Statistics
All data are presented as mean±standard error of the mean.
Unless otherwise noted statistical significance was calculat-
ed using student's t-tests. To take account of multiplicity in
group comparisons, one or two-way ANOVA followed by
Bonferroni's post-test were conducted (Neter et al., 1990).
Statistical significance was assigned as followed: *, Pb0.05;
**, Pb0.01, ***, Pb0.001.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.06.001.
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